This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Jun;14(7):564-5.

doi: 10.1016/S1470-2045(13)70170-0. Epub 2013 Apr 30.

A selective ALK inhibitor in ALK-rearranged patients

James Chih-Hsin Yang¹

Affiliations

PMID: 23639469
DOI: 10.1016/S1470-2045(13)70170-0

Comment

A selective ALK inhibitor in ALK-rearranged patients

James Chih-Hsin Yang. Lancet Oncol. 2013 Jun.

. 2013 Jun;14(7):564-5.

doi: 10.1016/S1470-2045(13)70170-0. Epub 2013 Apr 30.

Author

James Chih-Hsin Yang¹

Affiliation

¹ Department of Oncology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan. chihyang@ntu.edu.tw

PMID: 23639469
DOI: 10.1016/S1470-2045(13)70170-0

No abstract available

PubMed Disclaimer

Comment on

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T. Seto T, et al. Lancet Oncol. 2013 Jun;14(7):590-8. doi: 10.1016/S1470-2045(13)70142-6. Epub 2013 Apr 30. Lancet Oncol. 2013. PMID: 23639470 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information